肠杆菌科临床分离株对头孢吡肟的最低抑菌浓度增加。
Increased cefepime MIC for enterobacteriacae clinical isolates.
作者信息
Najafi Narges, Alikhani Ahmad, Babamahmoudi Farhang, Davoudi Alireza, Ghasemiyan Roya, Aliyan Shahriar, Shoujaiifar Arman
机构信息
Tropical Medicine and Microbial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
出版信息
Caspian J Intern Med. 2013 Spring;4(2):654-7.
UNLABELLED
Background : Cefepime was used as empirical treatment in ventilator-associated pneumonia (VAP) induced by gram-negative and gram-positive bacteria. This study aimed to determine the antimicrobial susceptibility pattern of cefepime against microorganism causing VAP in Mazandaran, North of Iran.
METHODS
This study was performed on VAP patients diagnosed with clinical pulmonary infection score (CPIS) scores in ICU of two hospitals. For each patient suspected of having VAP, quantitative culture of endotracheal aspiration (QEA) was performed and MIC was determined by micro dilution test. Data were collected and analyzed.
RESULTS
Thirty- five cases of enterobacteriaceae were isolated orderly including E coli 13, P. aeruginosa 11, Enterobacter 7 and K. pneumonia 4 cases. All the isolated E. coli, Enterobacter and Klebsiella, 54.5% of P. aeruginosa isolated were fully resistant to cefepime.
CONCLUSION
The results of this study show that cefepime is not a reasonable choice for empirical treatment of nosocomial pneumonia and VAP.
未标注
背景：头孢吡肟被用作革兰氏阴性菌和革兰氏阳性菌引起的呼吸机相关性肺炎（VAP）的经验性治疗药物。本研究旨在确定头孢吡肟对伊朗北部马赞德兰省引起VAP的微生物的抗菌敏感性模式。
方法
本研究对两家医院重症监护病房中临床肺部感染评分（CPIS）确诊为VAP的患者进行。对于每例疑似VAP的患者，进行气管内抽吸物定量培养（QEA），并通过微量稀释试验确定最低抑菌浓度（MIC）。收集并分析数据。
结果
依次分离出35例肠杆菌科细菌，包括13例大肠杆菌、11例铜绿假单胞菌、7例肠杆菌和4例肺炎克雷伯菌。所有分离出的大肠杆菌、肠杆菌和克雷伯菌，以及54.5%分离出的铜绿假单胞菌对头孢吡肟完全耐药。
结论
本研究结果表明，头孢吡肟不是医院获得性肺炎和VAP经验性治疗的合理选择。
Zotero 插件